Company news

Immatics N.V. news in 2025

Immatics N.V.'s news releases, calls and decks from 2025, newest first.

View company

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

December 11, 2025

Immatics Announces $125 Million Underwritten Offering

December 5, 2025

Immatics Announces Third Quarter 2025 Financial Results and Business Update

November 17, 2025

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

November 12, 2025

Immatics Appoints Amie Krause as Chief People Officer

October 27, 2025

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

October 19, 2025

Immatics Appoints Venkat Ramanan as Chief Financial Officer

October 1, 2025

Immatics Announces Second Quarter 2025 Financial Results and Business Update

August 13, 2025

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

May 31, 2025

Immatics Announces First Quarter 2025 Financial Results and Business Update

May 13, 2025

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

April 23, 2025

Immatics Announces Full Year 2024 Financial Results and Business Update

March 27, 2025

Decks in 2025